TICKERNOMICS Sign up
Last Update: 2023-12-23 06:02:36
Bionano Genomics Inc. ( BNGO ) https://www.bionanogenomics.com
1.62USD
Sector:
Healthcare
Industry:
Medical Instruments & Supplies
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
-89.34%
BNGO
SPY
30.72%
-79.10%
BNGO
SPY
112.82%
-96.82%
BNGO
SPY
201.04%
BNGO
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
56.70
33.96
1.43
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.25
1.69
0.48
-117.85
0.00
-0.16
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-1214.98
29.50
-645.27
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
16.3214
-201.51
-96.83
3.01
Other Earnings and Cash Flow Stats:
Bionano Genomics Inc. ( BNGO ) Net Income TTM ($MM) is -220.18
Bionano Genomics Inc. ( BNGO ) Operating Income TTM ($MM) is -220.73
Bionano Genomics Inc. ( BNGO ) Owners' Earnings Annual ($MM) is 0.00
Bionano Genomics Inc. ( BNGO ) Current Price to Owners' Earnings ratio is 0.00
Bionano Genomics Inc. ( BNGO ) EBITDA TTM ($MM) is -210.26
Bionano Genomics Inc. ( BNGO ) EBITDA Margin is -645.27%
Capital Allocation:
Bionano Genomics Inc. ( BNGO ) has paid 0.00 dividends per share and bought back -6.0309 million shares in the past 12 months
Bionano Genomics Inc. ( BNGO ) has reduced its debt by 0.207 million USD in the last 12 months
Capital Structure:
Bionano Genomics Inc. ( BNGO ) Interest-bearing Debt ($MM) as of last quarter is 6
Bionano Genomics Inc. ( BNGO ) Annual Working Capital Investments ($MM) are 42
Bionano Genomics Inc. ( BNGO ) Book Value ($MM) as of last quarter is 119
Bionano Genomics Inc. ( BNGO ) Debt/Capital as of last quarter is 5%
Other Balance Sheet Stats:
Bionano Genomics Inc. ( BNGO ) has 34 million in cash on hand as of last quarter
Bionano Genomics Inc. ( BNGO ) has 40 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Bionano Genomics Inc. ( BNGO ) has 35 common shares outstanding as of last quarter
Bionano Genomics Inc. ( BNGO ) has 0 million USD of preferred stock value
Academic Scores:
Bionano Genomics Inc. ( BNGO ) Altman Z-Score is -7.12 as of last quarter
Bionano Genomics Inc. ( BNGO ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
Bionano Genomics Inc. ( BNGO ) largest shareholder is Bank of New York Mellon Corp owning 12727 shares at 0.02 ($MM) value
Hannah Mamuszka(an insider) Bought 6578 shares of Bionano Genomics Inc. ( BNGO ) for the amount of $49992.80 on 2023-06-13
0.72% of Bionano Genomics Inc. ( BNGO ) is held by insiders, and 26.83% is held by institutions
Bionano Genomics Inc. ( BNGO ) went public on 2018-08-21
Other Bionano Genomics Inc. ( BNGO ) financial metrics:
FCF:-123.78
Unlevered Free Cash Flow:0.00
EPS:-12.86
Operating Margin:-1214.98
Gross Profit Margin:29.50
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-378.38
Beta:3.01
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Bionano Genomics Inc. ( BNGO ) :
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.